At a glance
ClinicalIndex Comparison Record- ✓Age ≥ 18 years
- ✓ECOG performance status 0 or 1
- ✓Obstructive colon cancer treated by defunctioning stoma
- ✓Pathologically confirmed adenocarcinoma ≥10 cm from anal verge (left transverse colon)
- ✕Contraindication to colectomy and/or anesthesia
- ✕Rectal cancer located within 10 cm of anal verge or below peritoneal reflection
- ✕Prior radiation therapy
- ✕Metastatic spread at baseline (lung, liver, peritoneal)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy : A Randomized Phase III Trial - COnCERTO (French 01-18)
In Brief
A Phase 3 clinical trial evaluating Neoadjuvant chemotherapy for Colon Cancer. Currently recruiting, targeting 232 participants across 28 sites.
Signals
Detailed Summary
The aim of this study is to determine whether chemotherapy prior to tumor removal (neoadjuvant chemotherapy), in patients undergoing treatment for colon cancer in occlusion (CCO), would improve the rate of patients able to benefit from "optimal" treatment, i.e. complete treatment (including all neoadjuvant and adjuvant chemotherapy cures). This new strategy, which would combine chemotherapy before surgery and possibly post-operatively (depending on tumor analysis), could improve the prognosis of occluded colon cancers by treating circulating micrometastases and/or inducing a reduction in tumor size, thereby increasing the rate of complete resection.
Study Details
Timeline
Interventions
Diverting stoma- neoadjuvant chemotherapy - colectomy - +/- adjuvant chemotherapy